GLP-1 medications explained: do you need Ozempic to lose weight?

GLP-1 receptor agonists — sold under brand names including Ozempic, Wegovy, Mounjaro, and Zepbound — have dominated health headlines for the past few years. Celebrities have endorsed them, social media has amplified them, and waiting lists for prescriptions have stretched for months. The hype is significant, but so is the underlying science. Here is what the evidence actually says.

What GLP-1 actually is

GLP-1 stands for glucagon-like peptide-1 — a hormone your body naturally produces in the gut after eating. Its job is to stimulate insulin secretion when blood sugar rises, slow down how quickly food moves through the stomach, and signal the brain that you are full. GLP-1 receptor agonist medications work by mimicking this hormone, amplifying and extending its effects far beyond what your body's natural production achieves. The active ingredient in Ozempic and Wegovy is semaglutide. Mounjaro and Zepbound contain tirzepatide, which targets both GLP-1 and a second related hormone called GIP — a dual action that appears to produce even greater effects on appetite and weight.

Why they were developed and who they are approved for

GLP-1 medications were originally developed and approved for treating type 2 diabetes. Clinicians noticed that patients were also losing significant amounts of weight, which led to higher-dose formulations being developed and approved specifically for obesity treatment. In the UK, Wegovy (semaglutide) is approved for adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition. In the US, eligibility criteria are similar. These are prescription medications intended for people with clinical obesity or significant weight-related health conditions — not general-purpose weight loss tools for everyone who wants to lose a few pounds.

How effective are they?

The clinical trial results are genuinely impressive. In trials of semaglutide at the doses used in Wegovy, participants lost an average of nearly 15 percent of their initial body weight over approximately 68 weeks. Tirzepatide trials showed even greater results — up to 21 percent body weight reduction over 72 weeks in some studies. These are larger effects than any previous non-surgical obesity treatment has achieved in randomised controlled trials. Beyond weight loss, GLP-1 medications have shown meaningful reductions in cardiovascular risk, improvements in blood pressure and cholesterol, and are now being explored for additional conditions including sleep apnoea and fatty liver disease.

The critical caveat: what happens when you stop

This is the most important thing to understand about GLP-1 medications that is often omitted from enthusiastic accounts. When people stop taking these drugs, the majority regain the weight they lost — often rapidly. GLP-1 medications suppress appetite through a pharmacological effect that ends when the drug leaves the system. They do not permanently change your relationship with food, your metabolism, or your eating habits. This is why medical guidance consistently frames them as long-term treatments rather than short-term interventions. Stopping the medication effectively removes the mechanism that was producing the weight loss, and without the dietary habits and understanding needed to maintain a calorie deficit independently, weight returns.

Side effects and risks

The most common side effects are gastrointestinal — nausea, vomiting, diarrhoea, and constipation — which affect a significant proportion of users, particularly when doses are increased. These often improve as the body adjusts. More serious but rarer risks include pancreatitis and gallbladder problems. People with a personal or family history of medullary thyroid cancer are advised not to use these medications. One concern that has emerged from clinical observation is muscle loss — GLP-1 medications reduce appetite broadly, and without sufficient protein intake and resistance training, a meaningful proportion of the weight lost may be muscle rather than fat. Long-term safety data are still accumulating, as widespread use at current scales is relatively recent.

What they cannot replace

GLP-1 medications work by making it easier to eat less — they are a powerful tool for reducing the calories-in side of the energy balance equation. They do not change the fundamental principle. A person on Wegovy who eats less and loses weight is still losing weight through a calorie deficit. Understanding this is important because it shapes how you use the medication and what happens when you stop. The people who do best on GLP-1 medications long term are those who use the reduced appetite window to establish better eating habits, build nutritional understanding, and maintain a sufficient protein intake with resistance training to preserve muscle. The medication creates the conditions for change — the habits create sustainability.

Do you need them to lose weight?

For the vast majority of people trying to lose weight, no. GLP-1 medications are a medical intervention for clinical obesity and related conditions, not a prerequisite for successful weight management. People lose weight every day without them, using the same principles that have always applied: a sustainable calorie deficit, adequate protein, and consistency over time. GLP-1 medications make the calorie deficit easier to maintain for people whose biology or medical history makes conventional approaches insufficient. For people who genuinely qualify medically and have struggled significantly despite serious effort, they can be a legitimate and life-changing intervention. For people who are moderately overweight and have not yet tried understanding their actual calorie needs and applying them consistently, medication is not the starting point.

The bottom line

GLP-1 medications are the most effective pharmaceutical tool for obesity treatment that has ever been developed. The clinical evidence for them is strong. They are not a scam, not a shortcut, and for people with clinical obesity they represent a genuine advance in treatment. But they are a tool that works by making it easier to eat less — which means the moment the tool is removed, the underlying energy balance principles reassert themselves. Understanding your calorie needs, building sustainable habits, and maintaining adequate protein and muscle mass are as important on GLP-1 medications as off them — perhaps more so.